Our Services

Cancer patients receive care from diagnosis to treatment and follow-up support. Through collaborative multidisciplinary team framework we provide the Medical Oncology aspect of cancer care, integrating with teams from surgical and radiation oncology and Palliative and Supportive care.

Our Staff

Oncology Department Staff 2018

Department Head

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Professor/Director of Oncology
Gastrointestinal Cancers Neuroendocrine Tumours

Senior Medical Staff

Dr. Muhammad Alamgeer MBBS MD MRCP FRACP
Head and Neck Cancer

Dr. Peter Briggs MBBS FRACP
Lung Cancer

Dr. Daphne Day MBBS (Hons), FRACP
Breast, Head and Neck Cancer and Phase 1 trials

A/Prof. Michael Franco MBBS FRACP FAChPM
Palliative Medicine and Gastrointestinal Cancer

Dr. Sophia Frentzas MBBS BSc (Hons) MRCP (UK) PHD MRCP (Med Onc UK) PGDip (Oncology) FRACP
Gastrointestinal, Phase 1 Trials and Gynaecological Cancer

Dr. Geraldine Goss MBBS FRACP MD MMED
Gynaecological Cancer

A/Prof. Marion Harris MBBS FRACP
Director of Familial Cancer, Gastrointestinal and Breast Cancer

Dr Gwo Yaw Ho MBChB, BSc (Hon) FRACP
Breast Cancer, Gynaecological Cancer

Dr. Edmond Kwan MBBS FRACP
Genitourinary Cancer

Dr. Ben Markman MBBS FRACP
Phase 1 Trials, Lung Cancer, Gastrointestinal Cancer

Dr. Sagun Parakh BSc MbChB FRACP
Phase 1 Trials, Lung Cancer and Neuro-Oncology

Dr. David Pook BMedSci (Hons) MBBS FRACP MD
Genitourinary Cancer

Dr. Ranjana Srivastava MBBS FRACP
Breast Cancer, Gastrointestinal Cancer, Geriatric Oncology

A/Prof. Andrew Strickland MBBS FRACP
Gastrointestinal Cancer

Dr. Kate Webber B.Sc (Med) MBBS (Hons 1) FRACP PhD
Breast Cancer, Gynaecological Cancer and Cancer Survivorship

Dr. Michelle White MBBS GDipPallMed FRACP
Breast Cancer

Support and Administration Staff 

Ms. Annette McClellan(Wed) and Ms. Courtney Robertson (Mon, Tues, Thu, Fri)

Oncology Department Secretary/PA to Professor Segelov.

E: PAtoProfSegelov@monashhealth.org
P: +61 3 8572 2392

Clinical Trials Fellows

Dr. Jane Yeojeong So

Dr. Caroline Lum

Advanced Trainees

Dr. Lisi Elizabeth Lim

Dr. Evangeline Samuel

Dr. Zhen Rong Siow

Dr. Rupert Strasser (Palliative Care January – July 2019)

Dr. Amanda Vo (Palliative Care July – December 2019)

Clinical Trials Research Staff

Ms. Karen Gillett
Oncology Research Manager

Ms. Merylyn Ryan
Oncology Research Operations Manager

Breast/Gynaecological Trials

breastgynae.oncresearch@monashhealth.org

Ms. Kim Brewin
Stream Lead/Study Coordinator

Ms. Jodie Prendergast
Study Coordinator

Early Phase Trials

earlyphase.oncresearch@monashhealth.org

Ms. Penny MacGuire
Stream Lead/Study Coordinator

Ms. Chris Brooks
Study Coordinator

Ms. Lauren Curtain
Study Coordinator

Mr. James Kinder
Study Coordinator

Ms. Michelle Puyer
Study Coordinator

Ms. India Patterson
Study Coordinator

Lung/Other Trials

lung.oncresearch@monashhealth.org

Ms. Laima Muceneikas
Stream Lead/Study Coordinator

Ms. Lindsay Thompson
Study Coordinator

Gastrointestinal (GI) Trials

gi.oncresearch@monashhealth.org

Ms. Shelley Firth
Stream Lead/Study Coordinator

Ms. Chris Poole
Study Coordinator

Ms. Cassandra Black
Study Coordinator

Genitourinary (GU) Trials

gu.oncresearch@monashhealth.org

Ms. Linda Garrett
Stream Lead/Study Coordinator

Ms. Louise Davis
Study Coordinator

Ms. Chloe Wu
Study Coordinator

Ms. Stephanie Kaladis
Study Coordinator

Ms. Deborah Chang
Study Coordinator

Ethics, Clinical Trials Assistant & Laboratory Assistants

Ms. Kelly Hoffman
Ethics Submission Lead

Ms. Julie Kavanagh
Feasibility Coordinator

Miss Holly Stewart
Clinical Trials Assistant

Ms. Megan Gillett
Clinical Trials Assistant

Ms. Rosemary  Widmann
Clinical Trials Assistant

Ms. Cate Glezos
Clinical Trials Assistant

Ms. Melinda Moss
Clinical Trials Assistant

Ms. Susan Alford
Laboratory Assistant

Ms. Dixita Desai
Laboratory Assistant

Oncology Finance

Email: Finance.Oncresearch@monashhealth.org

Ms. Emma Hoja
Oncology Research Finance Assistant

Nurse Practitioners

Ms. Vicki McLeod 

Oncology Translational Research Group – Click Here for Current Research

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP
Group Leader

Dr. Sophia Frentzas MBBS BSc (Hons) MRCP (UK) PHD MRCP (Med Onc UK) PGDip (Oncology) FRACP
Clinician Researcher

Dr Gwo Yaw Ho MBChB, BSc (Hon) FRACP
Clinician Researcher

Dr. Kate Webber B.Sc (Med) MBBS (Hons 1) FRACP PhD
Clinical Researcher

Dr. Daphne Day MBBS (Hons), FRACP
PhD Student

Dr. Sameer Greenall PhD, BSc (Hons)
Research Fellow

Dr. Ashalyn Watt PhD, Bsc (Hons).
Research Fellow

Ms. Anh Doan MRepSci
Research Assistant

Mr. Alastair Kin Hoo Kwok
Research Officer – PROMs and PREMs

Department Publications

2019

Wang Y, Logan S, Stern K, Wakefield CE, Cohn RJ, Agresta F, Jayasinghe Y, Deans R, Segelov E, McLachlan RI, Gerstl B. Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study. Supportive Care in Cancer. 2019 Jun:1-9.

Athauda A, Segelov. E, Khan Z, Chau I. 2018. Integrative molecular analysis of colorectal cancer and gastric cancer: what have we learnt? Cancer Treatment Reviews. Cancer Treatment Reviews.  1 Feb 2019, 73, p. 31-40

D. Day, S. Frentzas, C. A. Naidu, E. Segelov and M. Green. Current Utility and Future Applications of ctDNA in Colorectal Cancer , IntechOpen, DOI: 10.5772/intechopen.82316.

Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC? So Y, Frentzas S, Segelov, E. Hepatobiliary Surgery and Nutrition 2019 Aug 5

Wang Y; Logan S; Stern K; Wakefield C; Cohn R; Agresta F; Jayasinghe Y; Deans R; Segelov E; McLachlan R; Gerstl B; Sullivan E; Ledger W; Anazodo A. Supportive Oncofertility Care, Psychological Health and Reproductive Concerns: A Qualitative Study; Supportive Care in Cancer Jun 2019

Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant M, Pook D, Ng N, Graham L-J, Mangiola S, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T, Horvath L, Azad A. Prognostic utility of an androgen receptor splice variant-based gene signature in metastatic castration-resistant prostate cancer. European Urology Focus May 15th 2019.

Symonds EL, Pedersen SK, Murray D, Byrne SE, Hollington P, Rabbitt P, Jones FS, Segelov E;  Lazarus TS, LaPointe L, Young G. Circulating epigenetic biomarkers for sensitive detection of recurrent colorectal cancer. Submitted May 2019

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE) [Journal] Woodward, N, De Boer, R.H., Redfern, A, White, M, Young, J, Truman, M, Beith, J.
Clinical Breast Cancer, 2019, Feb 27.

2018

MacIntyre CR., Costantino V, Chen X, Segelov E, Chughtai, A, Kelleher A, Kunasekaran, M, Lane JM. 2018. Influence of population immunosuppression and past vaccination on smallpox reemergence. Emerging Infectious Diseases. 24:4:646-653.

Chin-Lenn L, Segelov E, De Boer RH, Marx GM, Hughes TM, McCarthy NJ, White S, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Mann B. 2018. “The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable.” Asia‐Pacific Journal of Clinical Oncology (2018).

Shapiro, S. Thayaneswaran, C. Underhill, K. Robledo, C. Karapetis, F. Day, L. Nott, J. Jefford, L. Chantrill, N. Pavlakis, N. Tebbutt, T. Price, M. Khasraw, G. V. Hazel, P. Waring, S. Tejpar, J. Simes, V. Gebski, J. Desai, E. Segelov. Cetuximab alone or with irinotecan for refractory KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study. Clinical Colorectal Cancer, 2018, Jun 8.

Singh S, Moody L, Chan D, Metz D, Strosberg J, Asmis T, Bailey D, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan S, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours. JAMA Oncology(2018) July 26.

Tang M, Price T, Shapiro J, Gibbs P, Haller D, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2018. Targeted therapies for metastatic colorectal cancer. Expert Review in Anticancer Therapy 18.10(2018): 991-1006

Tang M, Price JT, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis (2018). Expert Review of Anticancer Therapy. Volume 18(4), 339-349.

Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. Recurrence in Resectable Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4(4): 583-585.

Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis P, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2018. In Press

Ha FJ, Spain L, Dowling A, Kwan EM, Pezaro C, Day D, Chia PL, Tran B, Pook D, Weickhardt AJ. Timing of Brain Metastases Development in Metastatic Renal Cell Cancer patients treated with Targeted Therapies and Survival Outcomes: an Australian Multicentre Study. Asia Pac J Clin Oncol 2018. In Press

Fettke HC*, Kwan EM*, Azad AA. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr). In Press * Co-first author

C. J. McLaren., D. Day., D Croagh., A. Strickland., E. Segelov: Endoscopic Ultrasound in Pancreatic Cancer. Advances in Pancreatic Cancer, 09/2018; , ISBN: 978-1-78923-640-8, DOI:10.5772/intechopen.75211

P. Gibbs., V. Heinemann., N. K. Sharma., J. Taieb., J. Ricke., M. Peeters., M. Findlay., B. Robinson., C. Jackson., A. Strickland., V. Gebski., M. Van Buskirk., H. Zhao., G. Van Hazel: Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer 06/2018;, DOI:10.1016/j.clcc.2018.06.001

K. Shitara., M. Özgüroğlu., Y. Bang., M. Di Bartolomeo., M. Mandalà., M. Ryu., L. Fornaro., T. Olesiński., C. Caglevic., H. C Chung., K. Muro., E. Goekkurt., W. Mansoor., R. S McDermott., E. Shacham-Shmueli., X. Chen., C. Mayo., S. P. Kang., A. Ohtsu., C. S Fuchs., G. Lerzo., J. M. O’Connor., G. A. Mendez., J. Lynam., N. Tebbutt., M. Wong., A. Strickland., et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet 06/2018; 392(10142)

M. G. Lawrence., D. Obinata., S. Sandhu., L. A. Selth., S. Q. Wong., L. H. Porter., N. Lister., D. Pook., et al. Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European urology 74 (5), 562-572 (2018)

Sarah Q. To, Edmond M. Kwan, Heidi C. Fettke, Andrew Mant, Maria M. Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenho¨fer, Arun A. Azad. Expression of Androgen Receptor Splice Variant 7 or 9 in WholeBlood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer Eur Urol 2018. doi: 10.1016/j.eururo.2018.01.007. [Epub ahead of print]

Au L, Grant M, Haydon A, Segelov E, Antill Y, Oliva, Wilkins S, P McMurrick P, J Shapiro J. 2018. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: a cohort study of two cancer centres. International Journal of Surgery. 51:71-5.

Chi, W, Warner R, Chan D, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim M. 2018. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 47:321-25.

Chan DL, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology, 2018.

S. R. Davis., P. J. Robinson., F. Jane., S. White., M. White., R. J. Bell. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. The Journal of Clinical Endocrinology & Metabolism. November 2018, Volume 103(11), 4146-4154.

K. D. Marini., D. R. Croucher., R. A. McCloy., V. Vaghjiani, A. Gonzalez-Rajal, J. F. Hastings, V. Chin, A. Szczepny, K. Kostyrko, C. Marquez, W. S. N. Jayasekara., M. Alamgeer., V. Boolell., J. Z. R. Han., T. Waugh., H. C. Lee., S. R. Oakes., B. Kumar., C. A. Harrison., M. P. Hedger., N. Lorensuhewa., B. Kita., R. Barrow., B. W. Robinson., D. M. de Kretser, J. Wu., V. Ganju, E. A. Sweet-Cordero, A. Burgress, L. G. Martelotto, F. J. Rossello, J. E. Cain, D. N. Watkins. Inhibition of activing signalling in lung adenocarcinoma increase the therapeutic index of platinum chemotherapy. Sci Transl Med (10), 2018.

T. L. Leong., V. Gayevskiy., D. P. Steinfort., M. R. De Massy., A. Gonzalez-Rajal., K. D. Marini., E. Stone., V. Chin., A. Havryk., M. Plit., L. B. Irving., B. R. Jennings., R. A. McCloy., W. S. N. Jayasekara., M. Alamgeer., V. Boolell., A. Field., P. A. Russell, B. Kumar., D. J. Gough., A. Szczepny., V. Ganju., F. J. Rossello., J. E. Cain., A. T. Papenfuss., M. Asselin-Labat., M. J. Cowley., D. N. Watkins. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naïve, metastatic lung cancer. Oncogene, 2018

For Publications 2016 / 2017 click here

Department Abstracts

2019

Klein O, Kee D, Markman B, Chang Lee R, Michael M, Mileshkin L.R, Scott C.L, Linklater R, Menon S, Tebbutt N.C, Palmer J, Behren A, Cebon J.S. A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendrocrine, and gynaecological maligancies. Journal of Clinical Oncology 2019 37:15.

Balasubramanian A, Pick A, Kumar B, Prodanovic Z, Joshi P, Alamageer M. Treatment outcomes in malignant pleural mesothelioma: A Single center experience of systemic therapies and biomarkers. Journal of Clinical Oncology 2019 37:15.

Sweeny C, Martin A.J, Zielinkski R.R, Thomson A, Hsiang Tan T, Kaur Sandhu S, Reaume M.N, Pook D.W, Parnis F, North S.A McDermott S, McCaffrey J, Marx G.M, Lawrence N.J, Horvath L, Frydenberg M, Chowdhury S, Chi K.N, Stockler M.R, David I.D. Overall Survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. Journal of Clinical Oncology 37, 2019.

Symonds E, Pedersen S, Murray D, Byrne S, Hollington P, Rabbitt P, Jones F, Segelov, E, Lazarus T, Lapointe L, Young G. Performance comparison of the methylated BCAT1/IKZF1 ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer. Journal of Clinical Oncology 37 (15) Suppl; 3589 -3589.

Michael, M, Segelov, E. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. Journal Clinical Oncology 37 (15).

Kwan E, To S, Fettke H, Docanto M, Bukczynska P, Mant M, Waltham M, Pook D, Ng N, Graham L-J, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Horvath L, Azad A. Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC). Accepted for ASCO GU, Feb 2019, San Francisco

Millar J, Zheng H, Collopy B, SEGELOV E. The Development of an Australian National Standard Set of Clinical Indicators for Cancer Care to Monitor and Improve Care for Cancer Patients. Victorian Integrated Cancer Service Conference 2019.

 Bucki T, Srivastava R, Wagner I, SEGELOV E,  Sherwell S. Determining the feasibility and impact upon patients and clinicians on the use of a comprehensive geriatric assessment in a Geriatric Oncology clinic, Victorian Integrated Cancer Service Conference 2019

2018

Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov E, Bryant, A., Peckitt, C. and Roy, A., 2018. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology, 29(suppl_8), pp.mdy424-022

La C, Segelov E, McLeod V, Grewal G. An expanded role oncology pharmacist adds value to symptom and urgent review clinics. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Vol. 14. 2018.

Gan C, Gruner J, Segelov E.  Survey on patterns of travel for patients attending chemotherapy day units in Monash Health-A local experience. .ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Vol. 14. p113, 2018.

Lie G, Segelov E, Srivastava R. Implementation of a validated chemotherapy prediction tool in a busy oncology clinic. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Nov 1 Vol. 14, pp. 118-119).

Lum C, Rogers S, Sharma K, Marshall L, Sherwell S, Franco M, Hadley AM,  Segelov E, Day D. Implementation and results of the Victorian cancer patient experience survey (VCPES) at Monash Health. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Nov 1 Vol. 14, pp. 119-119

Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Segelov E, Paul J, Haydon A. Patients’ Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile? ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2018 Aug 1 Vol. 14, pp. 51-51.

Super L, Nguyen H, Segelov E, McLeod V, Degraves S, Fedele P, Vandenberg K, James K. A Pathway to Improving an Adolescent and Young Adult Oncology Service: Voices of Patients and Parents. 3rd Global Adolescent & Young Adult Cancer Congress. Dec 2018, Sydney.

Segelov E, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer  A, Wei B, Xu B,  Singh S. 2018. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), Annals of Oncology. 2018 Oct 1;29(suppl 8).

Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov E, Bryant, A., Peckitt, C. and Roy, A., 2018. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology, 29(suppl_8), pp.mdy424-022.

Singh, S., Bergsland, E., Card, C., Hope, T., Kunz, P., Laidley, D., Lawrence, B., Leyden, S., Michael, M., Modahl, L. and Myrehaug, S., Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. 2018. P1. 12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. Journal of Thoracic Oncology, 13(10), p.S575.

La C, Segelov E, McLeod V, Grewal G. An expanded role oncology pharmacist adds value to symptom and urgent review clinics. Accepted for COSA 2018 Nov, Perth.

Gan C, Gruner J, Segelov E. Survey on patterns of travel for patients attending chemotherapy day units in Monash Health- a local experience. Accepted for COSA 2018 Nov, Perth.

Super L, Nguyen H, Segelov E, McLeod V, Degraves S, Fedele P, Vandenberg K, James K. A Pathway to Improving an Adolescent and Young Adult Oncology Service: Voices of Patients and Parents. Accepted for 3rd Global Adolescent & Young Adult Cancer Congress. Dec 2018, Sydney.

Segelov E, Williams D, Chia J, Sieber O. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. Journal Clinical Onc 36 (4_suppl), 695-695.

Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M,Marx G, Price T, Reece W, Segelov E, Tebbutt N. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab. Journal Clinical Onc 36 (4_suppl), 719-719. Presented at ASCO GI 2018.

Blinman, D. Goldstein, A. Martin, M. Jefford, D. Boadle, N. Tebbutt, J. Paul, A. Haydon, E. Segelov, M. Stockler. Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? J Clin Oncol (2018) 36:15_suppl: 3602-3602.

Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus, IASLC 19th World Conference on Lung Cancer Sept 2018, Toronto.

Segelov E, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Singh S. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), European Society of Medical Oncology, Oct 2018, Munich.

M. Alamgeer., D. N. Watkins., I. Banakh., B. Kumar., D. J. Gough., B. Markman., Vinod Ganju. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer. Investigational New Drugs (2018) 36:288-298

Kwan EM, Semira M, Muttiah C, Beck S, Anton A, Tran B. Changing treatment landscape in the initial management of metastatic castrate-resistant prostate cancer (mCRPC): an Australian multi-centre retrospective study, Oral Abstract Presentation, MOGA Annual Scientific Meeting, 2018. Adelaide, Australia.

Fettke HC, Kwan EM, Mant A, Docanto MM, Bukczynska P, To SQ, Waltham M, Ng N, Parente P, Pezaro C, Azad AA. Plasma cell-free DNA concentration and outcomes in metastatic castrate-resistant prostate cancer patients treated with androgen receptor signalling inhibitors, Oral Abstract Presentation, ANZUP Annual Scientific Meeting, 2018. Sydney, Australia. * Selected for “Best of the Best” session

Kwan EM, To SQ, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhofer T, Azad AA. Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer, Poster Presentation, ASCO GU, 2018. San Francisco, USA. * Conquer Cancer Foundation Merit Award

L. Gulley, M. Borre, N. J. Vogelzang, S. Ng, N. Agarwal, C. C. Parker, D. W. Pook, P. Rathenborg, T. W. Flaig, J. Carles, N. D. Shore, L. Chen, C. R. Heery, W. R. Gerritsen, F. Priou, P. W. Kantoff. Results of PROSPECT: A randomized phase 3 of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. J Clin Oncol (2018) 36:15_suppl, 5006-5006.

Michael, D. W. Pook, V. Ganju, E. Link, G. C. Toner, R. J. Hicks, A. Matera, M. Thompson, C. Cullinane, I. Campbell, M. Burge, C. S. Karapetis. The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study. J Clin Oncol 36, 2018 (suppl; abstr 2563).

Desai, M. Voskoboynik, B. Markman, J. Hou, D. Zeng, T. Meniawy. Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclona antibody bgb-A333 alone and in combination with anti-PD-monoclonal antibody tislelizumab in patients with advanced solid tumors. J Clin Oncol 36, 2018 (suppl; abstr TPS3113).

 Meeting Abstracts and Posters for 2016 / 2017 click here

Updated June 2019